|
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 57.80 EUR | -1.57% |
|
-0.34% | +17.22% |
| 11-05 | CAC40 Attempts to Avoid a Seventh Consecutive Decline, Buoyed by Nasdaq Rebound |  |
| 11-05 | Paris Slows Further as Market Correction Looms | |
Business description: Eurofins Scientific SE
At the end of 2024, Eurofins Scientific SE owned a portfolio of over 200,000 analytical methods and had 950 laboratories located throughout the world.
Net sales are distributed geographically as follows: Europe (51%), North America (38.3%) and other (10.7%).
Number of employees: 65,000
Sales by Activity: Eurofins Scientific SE
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
Analytical Testing | 5.44B | 6.72B | 6.71B | 6.51B | 6.95B |
Geographical breakdown of sales: Eurofins Scientific SE
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
Europe | 3.18B | 4.05B | 3.56B | 3.36B | 3.6B |
North America | 1.92B | 2.18B | 2.53B | 2.54B | 2.7B |
Rest of The World | 425M | 603M | 733M | 725M | 770M |
Group Service Functions | - | - | - | 100K | - |
Inter-Segment Revenues | -84.2M | -114M | -112M | -111M | -119M |
Executive Committee: Eurofins Scientific SE
| Manager | Title | Age | Since |
|---|---|---|---|
Gilles Martin
CEO | Chief Executive Officer | 62 | 31/12/1986 |
Laurent Lebras
DFI | Director of Finance/CFO | - | 31/12/2014 |
Christian Wurst
PRN | Corporate Officer/Principal | - | 30/09/2019 |
François Vigneau
PRN | Corporate Officer/Principal | 59 | 31/10/1996 |
Composition of the Board of Directors: Eurofins Scientific SE
| Director | Title | Age | Since |
|---|---|---|---|
Gilles Martin
CHM | Chairman | 62 | 31/12/1986 |
Yves-Loïc Martin
BRD | Director/Board Member | 59 | 31/12/2014 |
Valérie Hanote
BRD | Director/Board Member | 59 | 31/12/1989 |
| Director/Board Member | 61 | 19/04/2017 | |
Pascal Rakovsky
BRD | Director/Board Member | 66 | 31/05/2020 |
Evie Roos
BRD | Director/Board Member | 58 | 31/12/2020 |
Ivo Rauh
BRD | Director/Board Member | 66 | 31/12/2020 |
Erica Monfardini
BRD | Director/Board Member | 54 | 24/04/2024 |
Holdings: Eurofins Scientific SE
| Name | Equities | % | Valuation |
|---|---|---|---|
| 6,199,371 | 3.4% | 442,100,084 $ | |
VIMTA LABS LIMITED 19.77% | 8,807,336 | 19.77% | 72,414,709 $ |
Company details: Eurofins Scientific SE
Group companies: Eurofins Scientific SE
| Name | Category and Sector |
|---|---|
Eurofins GeneScan Holding GmbH
 Eurofins GeneScan Holding GmbH Miscellaneous Commercial ServicesCommercial Services Part of Eurofins Scientific SE, Eurofins GeneScan Holding GmbH is a world leader in food, environment, pharma product testing & agroscience CRO services. The company is based in Freiburg im Breisgau, Germany. The German company has a network of more than 1,000 independent companies (900 laboratories) in 61 countries, offering over 200,000 analytical methods. The company was founded in 2011 and the CEO is Gilles G. Martin. |
Miscellaneous Commercial Services
|
Eurofins Discovery Services LUX Holding SARL
 Eurofins Discovery Services LUX Holding SARL Financial ConglomeratesFinance Part of Eurofins Scientific SE, Eurofins Discovery Services LUX Holding SARL functions as an investment holding Luxembourger company. The company is based in Luxembourg, Luxembourg. |
Financial Conglomerates
|
Wiener Neudorf Palmersstraße Real Estate GmbH |
Other Biotechnology & Medical Research
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.57% | -0.34% | +26.84% | -13.08% | 12.07B | |
| -2.15% | -1.20% | +3.90% | +6.33% | 47.62B | |
| +2.96% | +17.71% | +99.03% | +83.03% | 41.68B | |
| -2.04% | +2.69% | +12.17% | -3.53% | 36.81B | |
| -3.16% | +9.83% | +25.38% | +20.15% | 28.65B | |
| -0.73% | -0.58% | +88.57% | +160.03% | 16.5B | |
| +2.05% | +13.33% | +25.41% | +238.09% | 13.37B | |
| +5.95% | +9.52% | +71.18% | +88.56% | 13.23B | |
| -3.51% | -1.67% | -17.48% | -29.62% | 11.95B | |
| -3.05% | -7.22% | +26.70% | - | 11.81B | |
| Average | -1.39% | +3.66% | +36.17% | +61.11% | 23.37B | |
| Weighted average by Cap. | -1.61% | +4.64% | +37.06% | +48.19% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ERF Stock
- Company Eurofins Scientific SE
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition